What changed
What changedSanofi handed Cheplapharm 20 mature medicines, including Lovenox/Clexane, and three manufacturing sites, in exchange for a 26.4% stake in Cheplapharm; at the same time the company made a one‑time $1 billion payment to Regeneron to expand their global alliance with new immunology antibodies.

Upcoming events
As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →
Company history
October 2026
Sanofi: 12 recorded developments from 4 official sources in 2026-10.
- 2026-09-17: Sanofi and Cheplapharm to create new strategic partnership in mature medicines. Source
- 2026-09-17: Sanofi applies its deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more; its team is guided by one purpose: to chase the miracles of science to imp Source
- 2026-09-17: Sanofi and Cheplapharm announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide Source
- 2026-09-17: As part of the project, three manufacturing sites would be transferred to Cheplapharm: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees) Source
- 2026-09-17: The medicines being divested from Sanofi include Lovenox/Clexane (enoxaparin) Source
- 2026-10-01: In October 2026, Sanofi published the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference. Source
- 2026-10-01: Press Release dated October 1, 2026: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies. Source
- 2026-10-01: Regeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments Source
- 2026-10-01: companies to equally share development and commercialization costs, as well as any future profits Source
- 2026-10-01: Under the expanded license and collaboration agreement, the companies will co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4) and interleukin-4 receptor alpha (IL-4Rα) Source
- 2026-10-01: IL-13 antibody REGN20423 is currently in a phase 1 clinical study for atopic dermatitis, and the other three antibodies are expected to enter clinical studies in 2027 Source
- 2026-10-01: The agreement builds on the companies’ more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
The transaction is expected to be fully completed by the third quarter of 2027
Said September 17, 2026 · Period named: third quarter of 2027 · Source · Our article
Not yet checked against later reports.
The commercial transfer of the medicine portfolio is planned to begin in the first quarter of 2027
Said September 17, 2026 · Period named: first quarter of 2027 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| Millennium Management | 5,596,183 | $230,730,625 | +50.1% | Q3 2026 |
| Fidelity (FMR) | 3,967,153 | $163,565,714 | +7.8% | Q3 2026 |
| BlackRock | 1,988,502 | $81,985,920 | +2.7% | Q3 2026 |
| Capital Research Global Investors | 1,677,399 | $71,557,841 | +0.9% | Q2 2026 |
| Citadel Advisors | 750,639 | $30,948,846 | -59.5% | Q3 2026 |
| Bridgewater Associates | 428,389 | $17,662,478 | +107.1% | Q3 2026 |
| State Street | 24,276 | $1,004,199 | 0.0% | Q3 2026 |
| Wellington Management | 21,215 | $874,694 | — | Q3 2026 |
| T. Rowe Price | 1,613,375 | $77,733 | — | Q1 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.